“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”
“[SoluPro] enables “tuning” of protein production rates by optimizing for the best protein-folding and titer.”
“Sean McClain skipped the traditional academic route after graduating college…”
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil
AbSci to attend the Bio-Europe 2018 conference in Copenhagen, Denmark from 5th – 7th November 2018 If you would like to meet with an AbSci Business Development professional, please email us at partnering at abscibio.com
We’re excited to announce that AbSci made Seattle Business Magazine’s list of Washington’s 100 Best Companies to Work For! This year marks the 29th annual release of the Seattle Business Magazine’s 100 Best Companies to Work For list, as they look for the top...
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.
EY Announces Sean McClain of AbSci Entrepreneur Of The Year® 2018 Award Finalist in the Pacific Northwest region Vancouver, Washington May 7th, 2018 – EY announced that Founder and CEO Sean McClain of AbSci is a finalist for the Entrepreneur Of The Year® 2018 Award in...
AbSci says its genetically engineered E. coli expression platform has produced yields exceeding 20 g/L for difficult to express products and threatens the dominance of mammalian systems …
“There’s an electricity of discovery here like Genentech and Amgen,” said Dr. Herman. “AbSci’s ability to fold proteins is an innovative art form. This technology enables more efficient manufacturing, which will bring down the price of drugs.”